Evidence map›Paper›PMID 37692173›Full record

ArticleFrontiers in cellular and infection microbiology2023

Corrigendum: A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022.

Kaikai Yu, Bin Liu, Haotian Yu, Chengbiao Sun, Xuefeng Wang, Guorui Li, Mingxin Dong, Yan Wang, Jianxu Zhang, Na Xu and 1 more

Abstract readPublished Erratum
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Kaikai YuChangchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, Jilin, China.
Bin LiuState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Haotian YuChangchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, Jilin, China.
Chengbiao SunChangchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, Jilin, China.
Xuefeng WangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, Jilin, China.
Guorui LiCollege of Life Sciences and Food Engineering, Inner Mongolia Minzu University, Tongliao, China.
Mingxin DongChangchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, Jilin, China.
Yan WangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, Jilin, China.
Jianxu ZhangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, Jilin, China.
Na XuAcademic Affairs Office, Jilin Medical University, Jilin, Jilin, China.
Wensen LiuChangchun Veterinary Research Institute, Chinese Academy of Agricultural Science, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fcimb.2023.1155293.].

Indexed as

bispecific antibodyCOVID-19Omicron variantSARS-CoV-2single-chain variable fragment

Identifiers

PMID37692173
PMCPMC10484629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.